Folger W H, Halushka P V, Wilcox C S, Guzman N J
Department of Medicine, College of Medicine, University of Florida, Gainesville.
Eur J Pharmacol. 1992 Sep 1;227(1):71-8. doi: 10.1016/0922-4106(92)90144-k.
This study was designed to characterize rat glomerular thromboxane A2 (TxA2) receptors and compare them to rat platelet TxA2 receptors. The radioligand binding characteristics of the receptors were characterized using [125I][1S-(1 alpha,2 beta(5Z),3 alpha-(1E,3R*),4 alpha]-7-[3-(3-hydroxy-4-(4'-iodophenoxy)-1-butenyl)-7-oxabicyclo- [2.2.1]heptan-2yl]-5-heptenoic acid ([125I]BOP), a TxA2 agonist. Equilibrium binding with [125I]BOP, as well as competitive binding assays between [125I]BOP and 13-azapinane TxA2 receptors antagonists, were performed in rat glomerular membranes (RGM) and washed rat platelets (WRP). [125I]BOP identified a single class of TxA2 receptor sites in glomerular membranes with a Kd of 318 +/- 55 pM and a Bmax of 260 +/- 62 fmol/mg protein (n = 14). [125I]BOP was displaced by the TxA2 agonist 15S-hydroxy-11 alpha,9 alpha(epoxymethano)-prosta-5Z,13E-dienoic acid (U-46,619) (IC50 = 22 +/- 6 nM, n = 3), the antagonist SQ-29,548 (IC50 = 41 +/- 7 nM, n = 4), and stereoselectively by the antagonists (-)-9-chlorobenzyl-6-fluoro-1,2,3,4-tetrahydrocarbazol-1-yl acetic acid (L-657,925) (IC50 = 0.27 +/- 0.04 nM, n = 3) and (+)-9-chlorobenzyl-6-fluoro-1,2,3,4-tetrahydrocarbazol-1-yl acetic acid (L-657,926) (IC50 = 124 +/- 0 nM, n = 2). The ability of six 13-azapinane TxA2 antagonists to compete with [125I]BOP was evaluated. The rank orders for the 13-azapinanes showed no significant correlation between RGM and WRP.(ABSTRACT TRUNCATED AT 250 WORDS)
本研究旨在表征大鼠肾小球血栓素A2(TxA2)受体,并将其与大鼠血小板TxA2受体进行比较。使用[125I][1S-(1α,2β(5Z),3α-(1E,3R*),4α]-7-[3-(3-羟基-4-(4'-碘苯氧基)-1-丁烯基)-7-氧杂双环-[2.2.1]庚烷-2-基]-5-庚烯酸([125I]BOP),一种TxA2激动剂,对受体的放射性配体结合特性进行表征。在大鼠肾小球膜(RGM)和洗涤后的大鼠血小板(WRP)中进行了[125I]BOP的平衡结合以及[125I]BOP与13-氮杂双环壬烷TxA2受体拮抗剂之间的竞争性结合试验。[125I]BOP在肾小球膜中鉴定出一类单一的TxA2受体位点,其解离常数(Kd)为318±55 pM,最大结合容量(Bmax)为260±62 fmol/mg蛋白质(n = 14)。TxA2激动剂15S-羟基-11α,9α(环氧亚甲基)-前列腺-5Z,13E-二烯酸(U-46,619)(半数抑制浓度[IC50] = 22±6 nM,n = 3)、拮抗剂SQ-29,548(IC50 = 41±7 nM,n = 4)以及拮抗剂(-)-9-氯苄基-6-氟-1,2,3,4-四氢咔唑-1-基乙酸(L-657,925)(IC50 = 0.27±0.04 nM,n = 3)和(+)-9-氯苄基-6-氟-1,2,3,4-四氢咔唑-1-基乙酸(L-657,926)(IC50 = 124±0 nM,n = 2)能立体选择性地取代[125I]BOP。评估了六种13-氮杂双环壬烷TxA2拮抗剂与[125I]BOP竞争的能力。13-氮杂双环壬烷的排名顺序显示RGM和WRP之间无显著相关性。(摘要截断于250字)